Biogipuzkoa Health Research Institute, Group of Neuroimmunilogy, San Sebastián, Spain; Center for Biomedical Research Network in Neurodegenerative Diseases (CIBER-CIBERNED-ISCIII), Madrid, Spain.
Biogipuzkoa Health Research Institute, Group of Neuroimmunilogy, San Sebastián, Spain.
Neurotherapeutics. 2024 Oct;21(6):e00457. doi: 10.1016/j.neurot.2024.e00457. Epub 2024 Oct 15.
Multiple sclerosis (MS) is a chronic immune-mediated and heterogeneous disease characterized by demyelination, axonal damage, and physical and cognitive impairment. Recent studies have highlighted alterations in the microbiota of people with MS (pwMS). However, the intricate nature of the disease and the wide range of treatments available make it challenging to identify specific microbial populations or functions associated with MS symptoms and disease progression. This study aimed to characterize the microbiota of pwMS treated with the oral drug teriflunomide (TF) and compare it with that of pwMS treated with beta interferons (IFNβ), pwMS treated with no previous disease modifying therapies (naïve), and healthy controls. Our findings demonstrate significant alterations in both the composition and function of the gut microbiota in pwMS that are further influenced by disease-modifying therapies. Specifically, oral treatment with TF had a notable impact on the gut microbiota of pwMS. Importantly, the dysregulated microbial environment within the gut was associated with symptoms commonly experienced by pwMS, including fatigue, anxiety, and depression.
多发性硬化症（MS）是一种慢性免疫介导的异质性疾病，其特征是脱髓鞘、轴突损伤以及身体和认知功能障碍。最近的研究强调了多发性硬化症患者（pwMS）的微生物组发生改变。然而，由于疾病的复杂性和可用的治疗方法广泛，因此很难确定与 MS 症状和疾病进展相关的特定微生物群或功能。本研究旨在表征接受口服药物特立氟胺（TF）治疗的 pwMS 的微生物组，并将其与接受β干扰素（IFNβ）治疗的 pwMS、未接受过疾病修正治疗（naïve）的 pwMS 和健康对照进行比较。我们的研究结果表明，pwMS 的肠道微生物组在组成和功能上均发生显著改变，且疾病修正治疗进一步影响了其微生物组。具体来说，pwMS 口服 TF 治疗对其肠道微生物组有显著影响。重要的是，肠道内失调的微生物环境与 pwMS 常见的症状相关，包括疲劳、焦虑和抑郁。
